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Gastrointestinal stromal tumor with KIT mutation in 
neurofibromatosis type 1 
Hwan Namgung 
Department of Surgery, Dankook University College of Medicine, Cheonan, Korea
Multiple jejunalgastrointestinal stromal tumors (GISTs) were found in a 52-year-old woman with a history of neuro-
fibromatosis type 1. These tumors were composed of interlacing fascicles of uniform spindle cells with eosinophilic 
cytoplasm. Immunohistochemically, the tumor cells were positive for CD117, CD34 and negative for S-100, smooth muscle 
actin. Molecular analysis for activating mutations of KIT and PDGFRA was performed in two tumors. Contrary to sporadic 
GISTs, the NF1-associated GISTs are characterized by rare mutations of KIT or PDGFRA. But, one missense point mutation 
(Trp557Gly) was identified in KIT exon 11 of the extramural portion of the largest tumor in this case. The intramural portion 
of the largest tumor and the other tumor had wild type KIT and PDGFRA.
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INTRODUCTION
Type 1 neurofibromatosis patients (NF1) have a sig-
nificant predisposition to GISTs [1]. Ras activation 
through the somatic inactivation of the NF1 gene seems to 
be involved in the pathogenesis of NF1-associated GISTs 
[2]. Contrary to sporadic GISTs, the NF1-associated GISTs 
are characterized by a large number of small-sized tumors, 
typical location in the small intestine, and rare mutations 
of the KIT or PDGFRA [1]. However, occasional mutations 
of both the KIT and the PDGFRA have been reported in the 
NF1-associated GISTs, and the meaning of these muta-
tions remains unclear [3-6]. We present a case of NF1- asso-
ciated GISTs with a missense point mutation of the KIT in 
a 52-year old woman. 
CASE REPORT
Clinical summary
A 52-year-old woman with a history of NF1 presented 
with intermittent abdominal pain. She had been diag-
nosed as NF1 30 years ago and had a family history of NF1. 
Her skin showed numerous café au lait spots and multiple 
cutaneous neurofibromas over the whole body. A physical 
examination demonstrated a 20 × 15 cm palpable mass in 
the left abdomen. The abdominal computed tomography 
revealed a 15 × 9 × 7 cm tumor and several smaller masses 
along the jejunal loop (Fig. 1). On laparotomy, main tumor 
and numerous (more than 50) small nodular masses in the 
jejunum, located over 60 cm of the Treitz ligamen were 
found (Fig. 2). Segmental resection of the jejunum was per-GIST with KIT mutation in NF1
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Fig. 2. The resected segment of the jejunum shows a main tumor 
and numerous small nodular masses.
Fig. 3. Tumors are composed of interlacing fascicles of uniform 
spindle cells with eosinophilic cytoplasm and elongated nuclei 
(H&E, ×100).
Fig. 5. Sequencing of genomic DNA of the largest tumor 
demonstrates a missense point mutation of KIT exon 11 
(Trp557Gly, 1669T＞G).
Fig. 1. Abdominal computed tomography scans shows a large 
jejunal mass with several smaller masses and numerous small 
enhancing nodules at abdominal wall.
Fig. 4. Tumor cells are positive for KIT, CD117 (×200).
formed and the patient recovered uneventfully.
Pathologic findings 
The largest tumor was 18 × 11 × 6 cm, showed mainly ex-
tramural growth and connected to the ulcerative mass at 
the mucosal side. Focal hemorrhagic and necrotic portions 
were seen at the cut surface. Some of the multiple nodular 
masses, ranging in size from 0.2 to 4.0 cm, showed intra-
luminal umbilication. Histologically, the tumors consisted 
of interlacing fascicles of uniform spindle cells with eosi-
nophilic cytoplasm and elongated nuclei (Fig. 3). The larg-
est tumor had increased mitoses (19/50 high power fields) 
whereas the mitotic count of smaller tumors was less than 
5 per 50 high power fields. Immunohistochemical staining 
revealed tumor cells positive for CD117, CD34 and 
Vimentin, and negative for S-100 and smooth muscle actin Hwan Namgung
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(Fig. 4). 
The mutation analysis of KIT and PDGFRA
Genomic DNA was extracted from each paraffin blocks 
of two tumors, including the extramural and intramural 
portions of the largest one. Exons 9, 11, 13 and 17 of KIT 
and exons 12 and 18 of PDGFRA were amplified using the 
polymerase chain reaction (PCR) and then directly 
sequenced. The extramural portion of the largest tumor 
harbored a missense point mutation (Trp557Gly) of the 
KIT exon 11 (Fig. 5). The intramural portion of the largest 
tumor, as well as the other tumor, had wild type KIT and 
PDGFRA. 
DISCUSSION
Gastrointestinal stromal tumors (GISTs) are the most 
common mesenchymal tumors of the gastrointestinal 
tract, with characteristic morphologic, immunopheno-
typic and molecular features [7]. The gain of function KIT 
and PDGFRA mutations are considered to be a major driv-
ing force in the pathogenesis of sporadic, non-familial 
GISTs [8,9]. Activating mutations in the KIT gene are pres-
ent in up to 90% of the GISTs, and 35% of the GISTs lacking 
KIT mutations have activation mutations in the related re-
ceptor tyrosinekinase gene, PDGFRA. Most of the KIT mu-
tations are located on the following exons: 11 (the juxta-
membrane domain), 9 (the extracellular domain), 13 (the 
TK I domain) and 17 (the TK II domain); conversely, the 
PDGFRA mutations are usually located on the exons 12 or 
18. The KIT-JM domain encoded by the exon 11 is the most 
common mutational “hot spot” in GISTs [8]. A great ma-
jority of the KIT exon 11 mutations are deletion/dele-
tion-insertion and missense mutations. They represent the 
second most common type of KIT exon 11 mutations 
found in GISTs. These mutations cluster on the 5’ KIT exon 
11 and almost exclusively involve the KIT codons 557, 559 
and 560. Normally KIT and PDGFRA are activated by their 
ligands, stem cell factors and PDGFs. Ligand binding to 
the receptor EC domain results in dimerization of the re-
ceptors and phosphorylation of the tyrosines in their cyto-
plasmic TK domains. This leads to a phosphorylation cas-
cade of the tyrosine residues in multiple downstream sig-
naling molecules and to activation of the signal trans-
duction pathways, including the Ras/MAP kinase signal-
ing network. These KIT and PDGFRA mutations lead to li-
gand independent dimerization of the receptors and 
downstream the phosphorylation cascade, ultimately 
leading to activation of cellular proliferation.
In western countries, type 1 neurofibromatosis is a com-
mon autosomal dominant inherited disorder, with a prev-
alence of one in 3,000 live births. The syndrome results 
from either inherited or spontaneous germ-line mutations 
in the NF1 gene located at chromosome 17q11.2, which 
encodes the tumor suppressor gene, neurofibromin. In ad-
dition to multiple cutaneous and deep-seated neuro-
fibromas, patients with NF1 develop other evidence of the 
disease, including skin manifestations (e.g., axillary freck-
ling, café au lait spots), neurologic disorders, extra-in-
testinal neoplasm and neoplasm of the gastrointestinal 
tract (e.g., ampullary adenocarcinomas, somatostatino-
mas, and GISTs) [5]. 
The association between GISTs and type 1 neuro-
fibromatosis has been well established. The clinico-patho-
logic characteristics of the GISTs in NF1 are different from 
those of sporadic cases; most cases show multiple GISTs, 
predominantly involving the small intestine, and muta-
tions of the KIT or PDGFRA are rare [1]. Neurofibromin, 
the protein encoded by the NF1 gene, functions as a 
GTPase-activating protein for Ras by catalyzing the hy-
drolysis of the active Ras-GTP to an inactive Ras-GDP. 
Additional somatic inactivation of the wild type NF1 allele 
in the ICCs seems to be the molecular event underlying the 
GIST development in the NF1 setting [2]. Because of these 
genetic disorders, patients with NF1 are estimated to de-
velop GISTs at a rate of at least 45 times higher than spora-
dic cases and GISTs are considered as a type of the clinical 
symptoms seen in NF1.
Contrary to the sporadic GISTs, only occasional KIT and 
PDGFRA mutations have been reported in the NF1- asso-
ciated GISTs. Ten KIT/PDGFRA mutations have been re-
ported in the 87 investigated patients (Table 1). Takazawa 
et al. [3] identified two KIT (e.g., Pro627Leu and Ile654Thr) 
and two PDGFRA (e.g., Pro589Lys and Arg822Ser) mis-
sense mutations in two separate tumors of each patient. GIST with KIT mutation in NF1
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Table 1. Phenotypic and molecular characteristics of NF1 associated GIST with KIT or PDGFRA mutation
Case No. Location No. of GISTs Mutation Reference
1 Small bowel   1 Trp557_Lys558del in KIT exon 11 2
2 Small bowel 10 Lys558Lys in KIT exon 11
3 Small bowel 11 Arg822Ser in PDGFRA exon 18
Pro589Ser in PDGFRA exon 12 3
4 Small bowel  6 Ile654Thr in KIT exon 13
Pro627Leu in KIT exon 13
5 Small bowel More than 10 Val559 Asp in KIT exon 11 4
6 Stomach  2 Val560del in KIT exon 11
7 Small bowel  1 Ala502_Tyr503dup in KIT exon 9 5
8 Stomach  1 Asp842Val in PDGFRA exon 18
9 Small bowel More than 50 Trp557Gly in KIT exon 11 Present case
These mutations do not correspond to the ‘GIST-type’ of 
mutations and might therefore be random genetic events 
related to the tumor progression. Five ‘GIST type’ of muta-
tions were found in the NF1-associated GISTs. Yantiss at 
al. [5] found a point mutation (Val559Asp) of the KIT exon 
11 in three tumors from a patient. However, the presence 
of identical mutations in separated tumors raises the pos-
sibility of a germline mutation. Additionally, four muta-
tions were identified in two other studies [4,6], i.e., two 
in-frame deletions (Trp557_Lys558del and Val560del) of 
the exon 11 and one duplication (Ala502_Tyr503dup) of 
the exon 9 of KIT and one PDGFRA mutation (Asp842Val) 
in the exon 18. One missense mutation (Trp557Gly) of the 
KIT exon 11 was identified in the extramural portion of the 
largest tumor found in the presented case. We consider 
that this is a ‘GIST type’ mutation. Both the intramural 
portion of the largest tumor and the other tumor had wild 
type KIT and PDGFRA. The mutational feature of the pre-
sented case suggests that this mutation is not the initiation 
event, but might be an acquired genetic event which oc-
curred at the ‘hot spot’ of the KIT mutation in the late 
phase of the development of NF1-associated GISTs. 
Imatinib mesylate, a selective inhibitor of both KIT and 
PDGFRA, blocks these constitutively activated tyrosine 
kinases. This agent is currently being used as a molecular 
target drug for treating the GISTs and is showing a re-
markable therapeutic effect on most of the GISTs [7]. Most 
of the NF1-associated GISTs lack the KIT and PDGFRA 
mutation, therefore imatinib mesylate is not expected to 
be effective on these multiple tumors. However, there was 
one report demonstrating the therapeutic effect of im-
atinib  mesylate on the NF1-associated GIST w ith wild 
type KIT and PDGFRA [10]. Data on the effect of tyrosine 
kinase inhibitors on the NF1-associated GISTs with acti-
vating mutations are, nevertheless, limited.
Molecular analysis for more cases is needed to under-
stand the meaning of occasional occurrences of either KIT 
or PDGFRA mutations and to characterize their clinical 
features, including the response to tyrosine kinase in-
hibitors of the NF1-associated GISTs, according to the 
presence of the KIT or PDGFRA mutations.
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